Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicentric, Randomized, Double-blind, Placebo-controlled Study of TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis.

NCT06818058 is registered in ClinicalTrials.gov with Tarian Pharma as lead sponsor.

NCT NCT06818058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06818058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicentric, Randomized, Double-blind, Placebo-controlled Study of TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis.
Lead sponsor
Tarian Pharma
Phase
Phase 2
Overall status
Recruiting
Start date
January 20, 2025
Completion date
September 30, 2026
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

egfr inhibitor-associated rash